Akari Therapeutics Strengthens Balance Sheet and Prepares Phase 1 as Maxim Raises Rating to Buy
Backed by promising Trop2 ADC preclinical data, new financing, and strong ADC market momentum.
/ 185 items
#XY Analyst Up/Down↓
RBC Bullish on Nuvation Bio as Safusidenib Delivers Durable Responses in Glioma with New Phase 3 and Phase 2 Studies
Nuvation Bio reports strong long-term Phase 2 data for safusidenib (52% ORR, 79% PFS) and announces new Phase 3 and Phase 2 studies in IDH1-mutant glioma.
Maxim Initiates Buy Rating on Rein Therapeutics with $4 Price Target as LTI-03 Advances
Maxim highlights reduced risk and strong progress on LTI-03 for idiopathic pulmonary fibrosis. Phase 2 RENEW trial underway with topline data expected by end of 2027.
Zentalis Pharmaceuticals Gets Outperform Rating from Mizuho on Azenosertib Potential
Analyst highlights 75% upside potential ahead of key Phase 2 DENALI data readout for lead drug azenosertib.
Cash Constraints Force Wolfe to Downgrade Intellia to Underperform
Concerns over limited cash runway and slower clinical progress weigh on the stock.
JPMorgan Initiates Overweight on Tango Therapeutics with $46 Target as Pancreatic Cancer Data Impresses
Strong 92% ORR and 90% 6-month PFS in pancreatic cancer combo data fuel bullish sentiment.